Every figure is the balance as filed. Each filing badge opens the SEC index page for that fiscal year.
Structure
Capital structure
Assets plotted against the liabilities and equity stack, so you can see how the balance sheet is financed.
Liabilities and equity stack to the capital base; assets are the dashed reference line.
Composition
Capital mix
The same split read as a share of total capital rather than in absolute dollars.
Percentages are measured against total capital for each fiscal year.
Trend
Multi-year momentum
How assets, liabilities and equity have moved across the annual balance sheet window.
Switching between bar and line keeps the selected year order.
Doing some research...
Commentary
Commentary on CELANESE CORPORATION Balance Sheet
This explanation uses an earlier data snapshot or evidence version. Compare its generation date with the current filing figures.
Earlier AI snapshot · Generated Feb 16, 2026. The filing-backed figures above are the current source of truth.
Across the five-year span (noting 2025 data are not provided), Celanese’s balance sheet shows a sharp step-up in scale between 2021 and 2022 followed by modest swings through 2024. Total assets rose from $11,975m in 2021 to $26,272m in 2022 (≈+119%), then were essentially flat into 2023 ($26,597m, +1.2%) before falling to $22,857m in 2024 (−14.1%). Total liabilities moved in the same direction but with greater relative volatility: from $7,786m in 2021 to $20,635m in 2022 (+165%), down to $19,506m in 2023 (−5.5%) and then to $17,682m in 2024 (−9.4%). Equity rose more moderately from $4,189m in 2021 to $5,637m in 2022 (+34.6%), peaked at $7,091m in 2023 (+25.8%), then dropped to $5,175m in 2024 (−27.0%).
These moves increased leverage materially in 2022 (liabilities were ~78.6% of assets vs. 65.0% in 2021), eased somewhat in 2023, then ticked up again in 2024 (liabilities ≈77.4% of assets). The 2022 jump in assets and liabilities is consistent with a major corporate event (e.g., large acquisition, step-up in working capital or financing), while the 2023 improvement in equity and reduced liabilities suggests either strong operating/earnings momentum or balance-sheet rebalancing; the 2024 decline in equity and assets likely reflects either asset disposals, mark-to-market/impairments, working-capital drawdown, or returns of capital (dividends/share repurchases). For a capital‑intensive chemicals company like Celanese, these swings are not unusual, but the relatively high leverage (liabilities roughly 3.4x equity in 2024) warrants monitoring of debt levels, covenant headroom and cash‑flow generation going forward.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.
